Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
1.15(c) 1.1(c) 1.16(c) 1.14(c) 1.12(c) Last
3 047 433 3 077 213 2 159 185 2 143 387 1 386 065 Volume
-5.74% -4.35% +5.45% -1.72% -1.75% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 8,83x
Capi. / Sales2014 3,88x
Capitalization 139 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
03/16 PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
03/16 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Results of Operations a..
03/16 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
03/16 Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporat..
03/13 PROTALIX BIOTHERAPEUTICS INC : Today's Research Report on Trending Biotech Ticke..
03/09 Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corpora..
02/20 PROTALIX BIOTHERAPEUTICS : Announces Record Date for the 2017 Annual Meeting of ..
02/17 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Regulation FD Disclosur..
02/16 PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
02/15 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Shareholder Director No..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 458%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..151.69%139
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results